{"authors": [["Granier", "C", "C", "INSERMU970, Universit\u00e9 Paris Descartes Sorbonne Paris-Cit\u00e9, 56 Rue Leblanc Paris, France."], ["Blanc", "C", "C", "INSERMU970, Universit\u00e9 Paris Descartes Sorbonne Paris-Cit\u00e9, 56 Rue Leblanc Paris, France."], ["Karaki", "S", "S", "INSERMU970, Universit\u00e9 Paris Descartes Sorbonne Paris-Cit\u00e9, 56 Rue Leblanc Paris, France."], ["Tran", "T", "T", "INSERMU970, Universit\u00e9 Paris Descartes Sorbonne Paris-Cit\u00e9, 56 Rue Leblanc Paris, France."], ["Roussel", "H", "H", "INSERMU970, Universit\u00e9 Paris Descartes Sorbonne Paris-Cit\u00e9, 56 Rue Leblanc Paris, France."], ["Tartour", "E", "E", "INSERMU970, Universit\u00e9 Paris Descartes Sorbonne Paris-Cit\u00e9, 56 Rue Leblanc Paris, France."]], "date": "2017-08-08", "id": "29147623", "text": "Resident memory CD8+T cells (TRM) usually defined by the CD103 marker represent a new subset of long-lived memory T cells that remain in the tissues. We directly demonstrate their specific role in cancer vaccine-induced tumor regression. In human, they also seem to play a major role in tumor immunosurveillance.", "doi": "10.1080/2162402X.2017.1358841", "title": "Tissue-resident memory T cells play a key role in the efficacy of cancer vaccines.", "journal": ["Oncoimmunology", "Oncoimmunology"]}